Table 5. Post-operative complications by incision type.
| Periareolar (n=6) | Inframammary fold (n=6) | Hockey stick before 7/2019 (n=11) | Hockey stick after 7/2019 (n=4) | P | |
|---|---|---|---|---|---|
| Average time of follow-up (days) | 166.2±203.52 | 73.2±114.6 | 205.5 ±280.2 | 53.0±53.6 | 0.570 |
| Average time from surgery to BODY-Q (days) | 506.0±171.0 | 1,249.2±253.7 | 706.6±260.1 | 194±112.1 | <0.001** |
| Complications (any) | 3 (50.0%) | 2 (33.3%) | 6 (54.5%) | 2 (50.0%) | 0.945 |
| Wound dehiscence | 0 (0.0%) | 1 (16.7%) | 4 (36.4%) | 2 (50.0%) | 0.227 |
| Asymmetry | 1 (16.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0.593 |
| Hematoma | 2 (33.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0.103 |
| Seroma | 1 (16.7%) | 1 (16.7%) | 1 (9.1%) | 0 (0.0%) | 1.000 |
| Infection | 0 (0.0%) | 1 (16.7%) | 2 (18.2%) | 0 (0.0%) | 0.865 |
| Fat necrosis | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1.000 |
| Nipple necrosis | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1.000 |
| Post-operative ED visits | 1 (16.7%) | 1 (16.7%) | 4 (36.4%) | 2 (50.0%) | 0.608 |
| Re-admissions | 1 (16.7%) | 1 (16.7%) | 1 (9.1%) | 0 (0.0%) | 1.000 |
| Re-operations | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1.000 |
| Nipple reconstruction | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
| Fat grafting | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
| Scar revision | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
| Hematoma | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
| Mastopexy | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
| Recovery time | |||||
| Physical activity | 0.209 | ||||
| <2 weeks | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (25.0%) | |
| 2–4 weeks | 4 (66.7%) | 3 (50.0%) | 2 (18.2%) | 2 (50.0%) | |
| 4–6 weeks | 0 (0.0%) | 2 (33.3%) | 4 (36.4%) | 0 (0.0%) | |
| 6–8 weeks | 2 (33.3%) | 1 (16.7%) | 4 (36.4%) | 1 (25.0%) | |
| 8+ weeks | 0 (0.0%) | 0 (0.0%) | 1 (9.1%) | 0 (0.0%) | |
| Physical activity without limitation | 0.685 | ||||
| <2 weeks | |||||
| 2–4 weeks | 1 (16.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
| 4–6 weeks | 1 (16.7%) | 2 (33.3%) | 2 (18.2%) | 1 (25.0%) | |
| 6–8 weeks | 1 (16.7%) | 3 (50.0%) | 4 (36.4%) | 1 (25.0%) | |
| 8+ weeks | 3 (50.0%) | 1 (16.7%) | 5 (45.5%) | 2 (50.0%) |
Statistical significance observed in post-hoc analysis; **P<0.01. Time from surgery to BODY-Q, Cohort 1 vs. 2: P<0.001, 2 vs. 3: P<0.001, 2 vs. 4: P<0.001, 3 vs. 4: P=0.006.